Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Oncology

Journal Scan / Research · September 11, 2024

Tepotinib for Advanced Solid Cancers Harboring MET Exon 14 Skipping Mutations or Amplifications

ESMO Open

 

Additional Info

ESMO Open
A phase II study of tepotinib in patients with advanced solid cancers harboring MET exon 14 skipping mutations or amplification (KCSG AL19-17)
ESMO Open 2024 Aug 29;9(9)103668, EJ Kang, Y Yang, S Lee, YJ Kim, SM Lim, MJ Ahn, YJ Choi, Y Lee, TM Kim, I Kim, HK Ahn, HC Jeung, SI Lee, SY Oh, WK Bae, H Ryu, KH Park, KH Lee

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading